Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given ...

The following is a summary of "Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes ...

The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to pose a significant global health challenge due to its high ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

The trial will be a collaborative effort between the company, the Norwegian Cancer Society, and Cancer Research UK.

Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking.

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...